BPC‑157 and thymosin β4 compared: two repair pathways

BPC-157 and thymosin β4 are often discussed together because both are studied for tissue repair and both have been linked to the growth of new blood vessels. The similarity mostly ends there. They are different molecules, with different origins, different proposed mechanisms and evidence bases of very different maturity. This article compares them side by side. It is a scientific comparison, not a recommendation, and it does not suggest that either is preferable.

Our separate articles cover BPC-157's proposed mechanisms, thymosin β4 and TB-500 and the limited evidence for using them together.

What each molecule is

BPC-157 was introduced in 1993 as a fragment of a larger gastric-juice protein, within a hypothesis about the stomach's role in protecting other organs^[1]. Its sequence is GEPPPGKPADDAGLV^[2]. Thymosin β4 is a 4.9 kDa polypeptide that interacts with monomeric (G-) actin^[3]. β-Thymosins are the main intracellular proteins that hold actin monomers in reserve. They form a 1:1 complex with monomeric actin, preventing it from polymerising into filaments while keeping a pool available for when the cell needs them^[4].

Proposed mechanisms

Thymosin β4: actin biology and beyond

Thymosin β4's best-established function is intracellular: it buffers actin, which cells need in order to move and change shape^[4]. Outside cells, it is found in blood plasma and wound fluid. Effects attributed to extracellular thymosin β4 include chemotaxis, angiogenesis and inhibition of inflammation, although how these effects are mediated at the molecular level was unknown when reviewed in 2001^[4].

One signalling route has been described in the heart. Thymosin β4 formed a complex with the proteins PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt. In mice, treatment after coronary artery ligation increased ILK and Akt activity, improved early heart-muscle cell survival and improved cardiac function^[5].

BPC-157: nitric oxide and growth-factor signalling

No specific receptor for BPC-157 has been identified. Most mechanistic work concerns blood vessels and fibroblasts. In isolated rat aorta, BPC-157 caused vasodilation that depended on the endothelium and was mediated by nitric oxide. In endothelial cells, it activated a Src–caveolin-1–eNOS signalling pathway^[6]. The same research network reported that it increased expression and activation of vascular endothelial growth factor receptor 2 (VEGFR2)^[7]. It also increased growth hormone receptor expression in tendon fibroblasts^[8].

Angiogenesis: a shared theme, different evidence

Both peptides have been linked to angiogenesis, the formation of new blood vessels. The routes appear different.

• Thymosin β4 acted as a chemoattractant for endothelial cells, stimulating their migration four- to six-fold in chamber assays. It increased production of matrix metalloproteinases, which may degrade the basement membrane during vessel growth^[3]. In mouse heart development, it was essential for coronary vessel formation. It also stimulated outgrowth from adult epicardial tissue, giving rise to endothelial, smooth muscle and fibroblast cells^[9].
• BPC-157 increased vessel density in a chick embryo membrane assay and in endothelial tube-formation assays. It also accelerated the recovery of blood flow in ischaemic rat hind limbs, with increased VEGFR2 expression^[7].

The shared theme is real, but it does not mean a shared mechanism. One peptide acts through actin-related cell migration and cardiac progenitor signalling, the other through endothelial nitric oxide and VEGFR2 signalling.

Animal evidence

A 2019 review of BPC-157 in soft-tissue healing found consistently positive results. It noted that most studies used small rodent models and that only a handful of research groups had studied the peptide in depth^[13].

Cell research

Cell studies of both peptides exist from more than one laboratory. For thymosin β4, they include endothelial migration^[3], keratinocyte migration^[10] and heart-muscle cell survival^[5]. For BPC-157, independent work from Taiwan showed increased outgrowth from tendon explants and increased fibroblast migration and survival under oxidative stress, without a direct effect on proliferation^[14].

Human evidence

This is where the two diverge most clearly.

• Thymosin β4. A randomised, placebo-controlled phase 1 study in 40 healthy volunteers found intravenous thymosin β4 well tolerated, with no dose-limiting toxicity^[15]. A small randomised, double-masked phase 2 trial in nine patients with severe dry eye reported less discomfort and less corneal staining with thymosin β4 eye drops than with vehicle^[16]. A randomised venous ulcer trial has been described, but its published report covers design and early enrolment rather than final results^[17].
• BPC-157. A 2025 systematic review identified 35 preclinical studies and one clinical study^[18]. Another review counted three human pilot studies, with no rigorous trials^[19]. The largest is a retrospective chart review of knee pain, with telephone follow-up and no control group^[20].

These human data concern full-length thymosin β4 in pharmaceutical formulations, not TB-500, the short fragment often discussed alongside it. For BPC-157, the human data consist only of uncontrolled observations.

Maturity of the two evidence bases

Neither evidence base is mature enough to establish clinical benefit. But they are not at the same stage, and describing them as equivalent would misrepresent both.

Why overlap does not make them interchangeable

• Different targets. A shared outcome, such as more blood vessels, can arise from entirely different molecular routes. Interfering with one route tells us nothing about the other.
• Different tissues of strength. The thymosin β4 literature leans towards the heart, skin and eye, while the BPC-157 literature leans towards the gut, tendon and muscle.
• Different evidence types. Randomised human data exist for one and not the other. Evidence for thymosin β4 cannot be transferred to BPC-157, or to TB-500.
• Different safety questions. Because β-thymosins increase cell mobility, higher expression has been proposed as a possible contributor to metastasis^[4]. Long-term safety questions for BPC-157 have not been addressed in controlled human studies.

Summary

BPC-157 and thymosin β4 are both studied for tissue repair, and both have been linked to angiogenesis. Thymosin β4 is a well-characterised actin-buffering protein with described signalling pathways, research from several groups and small randomised human trials. BPC-157 is a synthetic gastric-derived peptide with no identified receptor, a literature dominated by one group, and only uncontrolled human reports. Their mechanisms, tissues of strongest evidence and stages of development differ. Mechanistic overlap is not evidence that one can stand in for the other.